Life Science REIT PLC Notice of Capital Markets Day (3428W)

TIDMLABS

RNS Number : 3428W

Life Science REIT PLC

17 April 2023

17 April 2023

LEI: 213800RG7JNX7K8F7525

LIFE SCIENCE REIT PLC

(the "Company", "Life Science REIT" or, together with its subsidiaries, the "Group")

Notice of Capital Markets Day

Life Science REIT (LSE: LABS), the real estate investment trust focused on UK life science properties, is pleased to announce that tomorrow, Tuesday 18 April 2023, it will host a capital markets day for institutional investors and research analysts at London's Francis Crick Institute, one of the foremost biomedical research centres in the UK.

The event will include presentations by Ironstone Asset Management, Life Science REIT's investment adviser, and by specialists in life science company formation and development and industry workplace design. Presenters will include Chris Hollowood, the Chief Executive Officer of Syncona Investment Management, and Jim Wilkinson, the Chief Financial Officer of Oxford Science Enterprises. The event will include a panel discussion and a Q&A session.

The event, on the morning of 18 April 2023, will be webcast live from 10.00am via the following link:

https://stream.buchanan.uk.com/broadcast/642423ae03867fad45f7be52

Shareholders are invited to send any questions by email in advance of the capital markets day to [e-mail] .

Following the event, a recording of the webcast will be made available on the Company's website, https://lifesciencereit.co.uk .

For further information, please contact Buchanan at [e-mail] .

No new price-sensitive information is expected to be announced on the day.

Enquiries:

 
 Link Company Matters Limited - Company 
  Secretary 
 [e-mail] 
 
 Ironstone Asset Management - Investment 
  Adviser 
 Simon Farnsworth, Managing Director 
 Joanna Waddingham, Head of Investor Relations 
  and Corporate Affairs 
 [e-mail] 
 
 Panmure Gordon (UK) Limited - Joint Corporate 
  Broker                                          [phone] 
 Alex Collins / Tom Scrivens 
 
 Jefferies International Limited - Joint 
  Corporate Broker                                [phone] 
 Tom Yeadon / Andrew Morris / Oliver Nott 
  / Harry Randall 
 G10 Capital Limited - AIFM                       [phone] 
 Verity Morgan-Jones / Paul Cowland 
 
 Buchanan - Financial PR                           [phone] 
 Mark Court / Henry Wilson / Verity Parker 
 [e-mail] 
 

Notes to editors

Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.

Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is benefiting from a buoyant early-stage funding environment, driving demand for laboratory space.

The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.

The Company's investment policy is focused on capital growth whilst also providing a growing level of income.

Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.

Further information is available at https://lifesciencereit.co.uk . To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/ .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBCGDSGBBDGXL

(END) Dow Jones Newswires

April 17, 2023 02:00 ET (06:00 GMT)